Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

Similar articles for PubMed (Select 19147772)

1.

The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma.

Chung JY, Hong SM, Choi BY, Cho H, Yu E, Hewitt SM.

Clin Cancer Res. 2009 Jan 15;15(2):660-7. doi: 10.1158/1078-0432.CCR-08-1084.

2.

The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas.

Lee D, Do IG, Choi K, Sung CO, Jang KT, Choi D, Heo JS, Choi SH, Kim J, Park JY, Cha HJ, Joh JW, Choi KY, Kim DS.

Mod Pathol. 2012 Jan;25(1):131-9. doi: 10.1038/modpathol.2011.133. Epub 2011 Aug 26.

3.

Expression and alterations of the PTEN / AKT / mTOR pathway in ameloblastomas.

Scheper MA, Chaisuparat R, Nikitakis NG, Sauk JJ.

Oral Dis. 2008 Sep;14(6):561-8. doi: 10.1111/j.1601-0825.2007.01421.x.

PMID:
18826385
4.

Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.

Xu G, Zhang W, Bertram P, Zheng XF, McLeod H.

Int J Oncol. 2004 Apr;24(4):893-900.

PMID:
15010827
5.

The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas.

Setsu N, Yamamoto H, Kohashi K, Endo M, Matsuda S, Yokoyama R, Nishiyama K, Iwamoto Y, Dobashi Y, Oda Y.

Cancer. 2012 Mar 15;118(6):1637-48. doi: 10.1002/cncr.26448. Epub 2011 Aug 11.

6.

Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.

Yothaisong S, Dokduang H, Techasen A, Namwat N, Yongvanit P, Bhudhisawasdi V, Puapairoj A, Riggins GJ, Loilome W.

Tumour Biol. 2013 Dec;34(6):3637-48. doi: 10.1007/s13277-013-0945-2. Epub 2013 Jul 6.

PMID:
23832540
7.

EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells.

Li T, Yang Y, Li X, Xu C, Meng L.

Mol Cell Biochem. 2012 Feb;361(1-2):19-29. doi: 10.1007/s11010-011-1082-0. Epub 2011 Sep 28.

PMID:
21952748
8.

Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma.

Kim HS, Kim GY, Lim SJ, Kim YW.

Pathobiology. 2012;79(2):84-93. doi: 10.1159/000334340. Epub 2012 Jan 27.

PMID:
22286903
9.

Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer.

Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ, Hewitt SM, Fujii T, Cordon-Cardo C, Jen J, Travis WD.

Clin Cancer Res. 2010 Jan 1;16(1):240-8. doi: 10.1158/1078-0432.CCR-09-0986. Epub 2009 Dec 15.

10.

A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.

Trigka EA, Levidou G, Saetta AA, Chatziandreou I, Tomos P, Thalassinos N, Anastasiou N, Spartalis E, Kavantzas N, Patsouris E, Korkolopoulou P.

Oncol Rep. 2013 Aug;30(2):623-36. doi: 10.3892/or.2013.2512. Epub 2013 May 31.

PMID:
23728071
11.

Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.

Sun CH, Chang YH, Pan CC.

Histopathology. 2011 Jun;58(7):1054-63. doi: 10.1111/j.1365-2559.2011.03856.x.

PMID:
21707707
12.

Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.

Long SH, He Y, Chen MH, Cao K, Chen YJ, Chen BL, Mao R, Zhang SH, Zhu ZH, Zeng ZR, Hu PJ.

J Dig Dis. 2013 Dec;14(12):662-9. doi: 10.1111/1751-2980.12095.

PMID:
23962154
13.

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.

Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL.

PLoS Med. 2008 Jan 22;5(1):e8. doi: 10.1371/journal.pmed.0050008.

14.

Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.

Pene F, Claessens YE, Muller O, ViguiƩ F, Mayeux P, Dreyfus F, Lacombe C, Bouscary D.

Oncogene. 2002 Sep 26;21(43):6587-97.

15.

Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.

Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D.

Clin Cancer Res. 2004 Oct 15;10(20):6779-88.

16.

Correlation between loss of PTEN expression and PKB/AKT phosphorylation in hepatocellular carcinoma.

Yang Z, Yi J, Li X, Long W.

J Huazhong Univ Sci Technolog Med Sci. 2005;25(1):45-7.

PMID:
15934306
17.

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.

Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS, Figlin RA.

Cancer. 2007 Jun 1;109(11):2257-67.

18.

Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology.

Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, O'Connor R, O'Neill C.

J Neurochem. 2005 Apr;93(1):105-17.

PMID:
15773910
19.

Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.

St-Germain ME, Gagnon V, Mathieu I, Parent S, Asselin E.

Int J Oncol. 2004 May;24(5):1311-24.

PMID:
15067356
20.

Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.

Kim JG, Chae YS, Sohn SK, Kang BW, Moon JH, Lee SJ, Jeon SW, Park JS, Park JY, Choi GS.

Oncology. 2010;79(3-4):278-82. doi: 10.1159/000320761. Epub 2011 Mar 16.

PMID:
21412012
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk